{
    "Trade/Device Name(s)": [
        "Atellica\u00ae IM High-Sensitivity Troponin I (TnIH)"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K241165",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062838"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MMI"
    ],
    "Summary Letter Date": "July 25, 2024",
    "Summary Letter Received Date": "April 26, 2024",
    "Submission Date": "April 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Cardiac troponin I"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Atellica\u00ae IM Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Master Curve Material"
    ],
    "Document Summary": "FDA 510(k) summary for Atellica IM High-Sensitivity Troponin I assay for quantitative measurement of cardiac troponin I and prognosis of mortality and major cardiac events using chemiluminescent sandwich immunoassay",
    "Indications for Use Summary": "For in vitro diagnostic use to quantitatively measure cardiac troponin I in human serum or plasma on the Atellica IM Analyzer to aid in diagnosis of acute myocardial infarction and prognosis of all-cause mortality and major adverse cardiac events in patients presenting with signs and symptoms of acute coronary syndrome",
    "fda_folder": "Clinical Chemistry"
}